Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention

Coronary Artery Disease

Volumn 17, Issue 4, 2006, Pages 379-384

  Lev, Eli I ^a   Tayyan, Nawar ^a   Raizner, Albert E ^a   Solomon, Stuart L ^a   Simmons, Donna ^a   Kleiman, Neal S ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Angioplasty; Drug eluting; Patient characteristics; Stents

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CARDIAC PATIENT; CATHETERIZATION; CLINICAL EXAMINATION; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DRUG ELUTING STENT; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; STENTS; TEXAS;

EID: 33748161113     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200606000-00009     Document Type: Article

References (29)

1. Holmes DR Jr, Firth BG, Wood DL. Paradigm shifts in cardiovascular medicine. J Am Coll Cardiol 2004; 43:507-512.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-1780.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
4. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al., E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093-1099.
5. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al., C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43:1110-1115.
6. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS substudy. Circulation 2004; 109:2273-2278.
7. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al., TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108:788-794.
8. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al., TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
9. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al., TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109:1942-1947.
10. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364:583-591.
11. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the 'real world': the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109:190-195.
12. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109:1366-1370.
13. Saia F, Lemos PA, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, et al. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 2004; 90:1183-1188.
14. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study. Circulation 2003; 108:1927-1929.
15. Goy JJ, Urban P, Seydoux C, De Benedetti E, Stauffer JC. Use of sirolimus-eluting coronary stents in routine clinical practice. Catheter Cardiovasc Intervent 2004; 62:26-29.
16. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2001; 103:3019-3041.
17. Ferreira AC, Peter AA, Salerno TA, Bolooki H, de Marchena E. Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center. Ann Thorac Surg 2003; 75:485-489.
18. Powell BD, Rihal CS, Bell MR, Zehr KJ, Holmes DR Jr. Anticipated impact of drug-eluting stents on referral patterns for coronary artery bypass graft surgery: a population-based angiographic analysis. Mayo Clin Proc 2004; 79:769-772.
19. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43:704-708.
20. FDA public health Web notification. Information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER coronary stent. October 29, 2003.
21. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364:1519-1521.
22. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109:701-705.
23. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005; 45:989-994.
24. Rao SV, Shaw RE, Brindis RG, Klein LW, Peterson ED. Predictors of drug eluting stent use in clinical practice: a report from the American College of Cardiology National Cardiovascular Disease Registry (ACC-NCDR). Circulation 2004; 110 (suppl):III-688.
25. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005; 45:1135-1141.
26. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003; 108:257-260.
27. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al., SES-SMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004; 292:2727-2734.
28. Lemos PA, Arampatzis CA, Saia F, Hoye A, Degertekin M, Tanabe K, et al. Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry). Am J Cardiol 2004; 93:633-636.
29. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al., TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005; 45:1172-1179.